Charles A Peloquin

Charles A Peloquin

UNVERIFIED PROFILE

Are you Charles A Peloquin?   Register this Author

Register author
Charles A Peloquin

Charles A Peloquin

Publications by authors named "Charles A Peloquin"

Are you Charles A Peloquin?   Register this Author

100Publications

-Reads

Protein Binding of First-Line Antituberculosis Drugs.

Antimicrob Agents Chemother 2018 Jul 26;62(7). Epub 2018 Jun 26.

Infectious Disease Pharmacokinetics Laboratory, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA

View Article
July 2018

Elevated Plasma Moxifloxacin Concentrations and g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.

Antimicrob Agents Chemother 2018 May 26;62(5). Epub 2018 Apr 26.

Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

View Article
May 2018

Effect of Genetic Variation of on Isoniazid and and on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.

Antimicrob Agents Chemother 2018 Mar 23;62(3). Epub 2018 Feb 23.

College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA

View Article
March 2018

Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.

Antimicrob Agents Chemother 2018 Jan 21;62(1). Epub 2017 Dec 21.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

View Article
January 2018

Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"

Antimicrob Agents Chemother 2018 Jan 21;62(1). Epub 2017 Dec 21.

Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

View Article
January 2018

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Expert Rev Clin Pharmacol 2017 Oct 18;10(10):1027-1036. Epub 2017 Aug 18.

b Department of Pharmacotherapy and Translational Research , University of Florida, College of Pharmacy , Gainesville , FL , USA.

View Article
October 2017

Reply to Srivastava et al., "pH Conditions under Which Pyrazinamide Works in Humans".

Antimicrob Agents Chemother 2017 Sep 24;61(9). Epub 2017 Aug 24.

National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia.

View Article
September 2017

Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt.

Clin Infect Dis 2017 Aug;65(4):704-705

College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville.

View Article
August 2017

Polymyxin Combinations Combat Harboring and : Preparation for a Postantibiotic Era.

MBio 2017 07 25;8(4). Epub 2017 Jul 25.

Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA

View Article
July 2017

Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.

Antimicrob Agents Chemother 2017 06 24;61(6). Epub 2017 May 24.

University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, Florida, USA

View Article
June 2017

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.

Pharmacogenet Genomics 2017 05;27(5):190-196

aDepartment of Pharmacotherapy and Translational Research bCenter for Pharmacogenomics, College of Pharmacy, University of Florida cUniversity of Florida Health Shands Hospital, Gainesville dDepartment of Pharmaceutics eCenter for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando fDepartment of Medicine, Division of Hematology and Oncology gDepartment of Medicine, Division of Cardiology, College of Medicine, University of Florida, Gainesville, Florida, USA.

View Article
May 2017

The pharmacological challenges of treating tuberculosis and HIV coinfections.

Expert Rev Clin Pharmacol 2017 Feb 28;10(2):213-223. Epub 2016 Nov 28.

a Department of Pharmacotherapy and Translational Research , College of Pharmacy.

View Article
February 2017

Reply to Alffenaar et al.

Clin Infect Dis 2017 Jan 26;64(1):105-106. Epub 2016 Oct 26.

University of California, San Francisco.

View Article
January 2017

Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistance.

Int J Tuberc Lung Dis 2017 01;21(1):121-123

Infectious Disease Pharmacokinetics Laboratory, University of Florida College of Pharmacy and Emerging Pathogens Institute, Gainesville, FL, USA.

View Article
January 2017

Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.

Antimicrob Agents Chemother 2016 11 21;60(11):6591-6599. Epub 2016 Oct 21.

Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University School of Medicine, and University Hospitals Case Medical Center, Cleveland, Ohio, USA.

View Article
November 2016

Tuberculosis therapy for 2016 and beyond.

Expert Opin Pharmacother 2016 Oct 19;17(14):1859-72. Epub 2016 Aug 19.

b College of Pharmacy , University of Florida , Gainesville , FL , USA.

View Article
October 2016

Rifapentine for the treatment of latent tuberculosis.

Expert Rev Clin Pharmacol 2016 Aug 22:1-9. Epub 2016 Aug 22.

a Department of Pharmacotherapy and Translational Research, College of Pharmacy , University of Florida , Gainesville , FL , USA.

View Article
August 2016

Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis.

J Antimicrob Chemother 2016 06 6;71(6):1738. Epub 2016 Feb 6.

Department of Pediatrics, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY, USA.

View Article
June 2016

Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.

Pediatr Infect Dis J 2016 Apr;35(4):414-21

From the *Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; †Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida; ‡Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; §Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; ¶North Bay Pediatrics, Vallejo, California; ‖Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado; **TB/Leprosy Program, Federated States of Micronesia (FSM); ††Francis J. Curry International TB Center, San Francisco, California; and ‡‡Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida.

View Article
April 2016

Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.

Antimicrob Agents Chemother 2015 16;59(6):3149-55. Epub 2015 Mar 16.

Division of Infectious Diseases Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA Departments of Epidemiology and Global Health, Emory Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

View Article
February 2016

Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature.

BMC Infect Dis 2015 Aug 12;15:327. Epub 2015 Aug 12.

The Infectious Disease Pharmacokinetics Laboratory, Gainesville, Florida, USA.

View Article
August 2015

Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.

Antimicrob Agents Chemother 2015 Jul 13;59(7):3800-7. Epub 2015 Apr 13.

University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, and the Emerging Pathogens Institute, Gainesville, Florida, USA

View Article
July 2015

Voriconazole monitoring in children with invasive fungal infections.

J Pediatr Pharmacol Ther 2015 Jan-Feb;20(1):17-23

Infectious Disease Pharmacokinetics Laboratory, Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida ; Emerging Pathogens Institute, University of Florida, Gainesville, Florida.

View Article
April 2015

Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014.

Tuberc Respir Dis (Seoul) 2015 Apr 2;78(2):78-84. Epub 2015 Apr 2.

Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.

View Article
April 2015

Medications and monitoring in nontuberculous mycobacteria infections.

Clin Chest Med 2015 Mar 18;36(1):55-66. Epub 2014 Dec 18.

Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy, and Emerging Pathogens Institute, University of Florida, 1600 Southwest Archer Road, Gainesville, FL 32610-0486, USA. Electronic address:

View Article
March 2015

Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Antimicrob Agents Chemother 2014 18;58(2):782-8. Epub 2013 Nov 18.

Kibong'oto National Tuberculosis Hospital, Kilimanjaro, Tanzania.

View Article
September 2014

Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.

Antimicrob Agents Chemother 2014 Aug 19;58(8):4904-10. Epub 2014 May 19.

College of Pharmacy, University of Florida, Gainesville, Florida, USA.

View Article
August 2014

CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

Pharmacotherapy 2014 Jul 7;34(7):703-18. Epub 2014 Feb 7.

Icahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine, New York, New York; Department of Pharmacy, The Mount Sinai Hospital, New York, New York.

View Article
July 2014

Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Drugs 2014 Jun;74(8):839-54

Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, 1600 SW Archer Rd., Rm P4-33, PO Box 100486, Gainesville, FL, 32610-0486, USA.

View Article
June 2014

Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.

J Antimicrob Chemother 2014 Apr 15;69(4):1079-85. Epub 2013 Dec 15.

Medical Service, Department of Veterans Affairs Medical Center, San Antonio, TX, USA.

View Article
April 2014

Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.

Pharmacotherapy 2014 Mar 13;34(3):265-71. Epub 2014 Jan 13.

Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; The Miriam Hospital, Providence, Rhode Island.

View Article
March 2014

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.

Antimicrob Agents Chemother 2013 Aug 3;57(8):3910-6. Epub 2013 Jun 3.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article
August 2013

Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.

Antimicrob Agents Chemother 2013 Mar 7;57(3):1535-7. Epub 2013 Jan 7.

Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article
March 2013

Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis.

Pharmacotherapy 2013 Jan;33(1):e1-8

Department of Pharmacotherapy and Translational Research, College of Pharmacy, and the Emerging Pathogens Institute, University of Florida, Gainesville, Florida 32610-0486, USA.

View Article
January 2013

Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.

J Antimicrob Chemother 2012 Sep 8;67(9):2182-90. Epub 2012 Jun 8.

Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.

View Article
September 2012

The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.

Am J Respir Crit Care Med 2012 Sep 28;186(6):559-65. Epub 2012 Jun 28.

Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA.

View Article
September 2012

Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.

Ann Pharmacother 2012 Sep 7;46(9):e22. Epub 2012 Aug 7.

Department of Pharmacy Practice & Science, University of Arizona, Tucson, AZ, USA.

View Article
September 2012

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Antimicrob Agents Chemother 2012 Aug 4;56(8):4331-40. Epub 2012 Jun 4.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article
August 2012

Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.

Antimicrob Agents Chemother 2012 Jul 23;56(7):3712-9. Epub 2012 Apr 23.

Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.

View Article
July 2012

Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Antimicrob Agents Chemother 2012 Jul 30;56(7):3726-31. Epub 2012 Apr 30.

Departments of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article
July 2012

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Antimicrob Agents Chemother 2012 Jun 2;56(6):3114-20. Epub 2012 Apr 2.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article
June 2012

Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

Pharm Res 2012 Apr 9;29(4):972-82. Epub 2011 Dec 9.

Department of Pharmacotherapy & Translational Research, University of Florida, Gainesville, Florida 32610-0486, USA.

View Article
April 2012

Antituberculosis therapy for 2012 and beyond.

Expert Opin Pharmacother 2012 Mar 15;13(4):511-26. Epub 2012 Feb 15.

University of Florida, College of Medicine, 1600 SW Archer Road, PO Box 100486, Gainesville, FL 32610-0486, USA.

View Article
March 2012

Pharmacokinetic mismatch of tuberculosis drugs.

Antimicrob Agents Chemother 2012 Mar;56(3):1666; author reply 1667

View Article
March 2012

Paediatric use of second-line anti-tuberculosis agents: a review.

Tuberculosis (Edinb) 2012 Jan 25;92(1):9-17. Epub 2011 Nov 25.

Desmond Tutu TB Centre, Faculty of Health Sciences, Stellenbosch University, South Africa.

View Article
January 2012

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Antimicrob Agents Chemother 2011 Dec 19;55(12):5485-92. Epub 2011 Sep 19.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article
December 2011

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.

Am J Respir Crit Care Med 2011 May 17;183(9):1254-61. Epub 2011 Feb 17.

Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1501 Orleans Street, Baltimore, MD 21231, USA.

View Article
May 2011

Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Antimicrob Agents Chemother 2011 Apr 31;55(4):1781-3. Epub 2011 Jan 31.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.

View Article
April 2011

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Antimicrob Agents Chemother 2011 Mar 6;55(3):1237-47. Epub 2010 Dec 6.

Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.

View Article
March 2011

PA-824 exhibits time-dependent activity in a murine model of tuberculosis.

Antimicrob Agents Chemother 2011 Jan 11;55(1):239-45. Epub 2010 Oct 11.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231-1002, USA.

View Article
January 2011

The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters.

J Antimicrob Chemother 2010 Oct 6;65(10):2172-5. Epub 2010 Aug 6.

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article
October 2010

Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

J Antimicrob Chemother 2010 Apr 31;65(4):729-34. Epub 2010 Jan 31.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article
April 2010

Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.

Infect Dis Obstet Gynecol 2009 10;2009:621780. Epub 2010 Jan 10.

Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA.

View Article
April 2010

Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.

Antimicrob Agents Chemother 2009 Sep 29;53(9):3981-4. Epub 2009 Jun 29.

Infectious Disease Pharmacokinetics Laboratory, National Jewish Health, Denver, Colorado, USA.

View Article
September 2009

Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.

Pharm Res 2009 Aug 30;26(8):1847-55. Epub 2009 Apr 30.

Harvard School of Engineering and Applied Sciences, 29 Oxford Street, Pierce 322, Cambridge, Massachusetts 02138, USA.

View Article
August 2009

Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis.

Am J Trop Med Hyg 2009 Aug;81(2):322-9

Clinical Research Unit and Institute of Biomedicine/Center for Global Health, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.

View Article
August 2009

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.

Braz J Infect Dis 2009 Jun;13(3):210-7

Clinical Research Unit & Institute of Biomedicine, Center for Global Health, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza.

View Article
June 2009

Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.

Pharmacotherapy 2009 May;29(5):503-10

Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

View Article
May 2009

Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Antimicrob Agents Chemother 2009 Apr 12;53(4):1338-43. Epub 2009 Jan 12.

Harvard School of Engineering and Applied Sciences, Cambridge, Massachusetts 021381, USA.

View Article
April 2009

Tuberculosis pharmacotherapy: strategies to optimize patient care.

Expert Opin Pharmacother 2009 Feb;10(3):381-401

Department of Global Health & Social Medicine, Harvard Medical School, 643 Huntington Ave., 4th Floor, Boston, MA 02215, USA.

View Article
February 2009

Treatment of a tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs.

Can Respir J 2008 Jul-Aug;15(5):241-3

Department of Medicine, University of Alberta, Edmonton, Canada.

View Article
December 2008

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.

Am J Respir Crit Care Med 2008 Dec 11;178(11):1180-5. Epub 2008 Sep 11.

Núcleo de Doenças Infecciosas Centro de Ciências da Saúde, Universidade Federal do Espírito Santo, Av. Marechal Campos, 1468 Maruípe,Vitória-ES Brazil, CEP 29040-091.

View Article
December 2008

Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.

Antimicrob Agents Chemother 2008 Nov 11;52(11):4137-40. Epub 2008 Aug 11.

Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523, USA.

View Article
November 2008

Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.

Antimicrob Agents Chemother 2008 Nov 2;52(11):4037-42. Epub 2008 Sep 2.

Divisions of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland 21231, USA.

View Article
November 2008

Concomitant use of voriconazole and rifabutin in a patient with multiple infections.

Pharmacotherapy 2008 Aug;28(8):1076-80

Department of Pharmacy, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA.

View Article
August 2008

Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).

J Am Assoc Lab Anim Sci 2008 Jul;47(4):41-5

Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA.

View Article
July 2008

Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

Bioorg Med Chem Lett 2008 May 18;18(10):3029-33. Epub 2008 Apr 18.

Institute of Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA.

View Article
May 2008

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Antimicrob Agents Chemother 2008 Mar 10;52(3):852-7. Epub 2007 Dec 10.

Infectious Disease Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, CO 80206, USA.

View Article
March 2008

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

PLoS Med 2007 Dec;4(12):e344

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

View Article
December 2007

Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.

J Antimicrob Chemother 2007 Oct 1;60(4):819-23. Epub 2007 Aug 1.

Michigan State University School of Medicine, B320 Life Science Building, East Lansing, MI 48824, USA.

View Article
October 2007